Tel Aviv-based cannabis company Syqe Medical has introduced the world’s first pharmaceutical-grade metered-dose cannabis inhaler in Israel.
The Syqe Inhaler has received the world’s first ever regulatory approval from the Israeli Ministry of Health as a medical device combined with cannabis and will be available for purchase by licensed patients in Israel.
Breakthrough Drug Delivery Device
The Syqe Inhaler, a non-combustion drug delivery device, allows physicians to prescribe precise dosages meeting pharmaceutical standards.
The company’s breakthrough drug delivery technology introduces complex respiration technique automation, electronic selective dosing and remote clinical monitoring and dose control, significantly expanding the applicability of the platform well beyond cannabis, Syqe said in a statement.
The devices will be marketed and distributed by Teva (NYSE:TEVA) Israel. The cannabis in the Syqe inhaler is produced under controlled pharmaceutical conditions, complying with good manufacturing practices.
“80% of cannabis patients inhale the plant. For too long, physicians who wish to treat these patients have been without the most basic clinical knowledge on dosing, efficacy and adverse events of cannabis,” Syqe Medical CEO and Founder Perry Davidson stated.
“For eight years Syqe has been developing proprietary technologies for the administration of raw plants, and through our clinical trials we were able to determine the recommended dosage of inhaled cannabis down to the microgram. This launch marks the beginning of a new chapter in pain treatment, one in which physicians can confidently prescribe precise dosages of cannabis, and patients can reap the rewards, effectively and responsibly,” Davidson added.
With the launch of this drug delivery device, Syqe aims to transform medical cannabis into a mainstream medical treatment.
The company believes that the Syqe Inhaler and supporting clinical research will unlock the global medical cannabis market by eliminating uncertainty surrounding dosage administration and alleviating physician concerns with regards to adverse events and psychoactivity. In turn, this will enable greater physician adoption of medical cannabis.